^
Association details:
| Biomarker: | CDKN2A mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001).
Published date:
05/19/2021
Excerpt:
The most mutated genes were TP53 (51%), KRAS (20%), CDKN2A (18%) and SMAD4 (16%)….Gene mutation profiling by NGS suggested mutated PI3K pathway might associate with shorter PFS.
Trial ID:
